Cargando…
IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin
The complexity of the IGF-1 signalling axis is clearly a roadblock in targeting this receptor in cancer therapy. Here, we sought to identify mediators of resistance, and potential co-targets for IGF-1R inhibition. By using an siRNA functional screen with the IGF-1R tyrosine kinase inhibitor (TKI) BM...
Autores principales: | O'Flanagan, Ciara H., O'shea, Sandra, Lyons, Amy, Fogarty, Fionola M., McCabe, Nuala, Kennedy, Richard D., O'Connor, Rosemary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302955/ https://www.ncbi.nlm.nih.gov/pubmed/27472395 http://dx.doi.org/10.18632/oncotarget.10862 |
Ejemplares similares
-
The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo
por: Vendetti, Frank P., et al.
Publicado: (2015) -
Stress-Activated Protein Kinases (SAPKs) in IGF-I Mediated Cell Survival
por: Krause, Darren, et al.
Publicado: (2001) -
Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma: ATM, ATR and FA in lung carcinoma
por: Beumer, Jan H., et al.
Publicado: (2015) -
IGF-1 Receptor and Adhesion Signaling: An Important Axis in Determining Cancer Cell Phenotype and Therapy Resistance
por: Cox, Orla T., et al.
Publicado: (2015) -
The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link
por: Bowers, Laura W., et al.
Publicado: (2015)